Phase 3 data shows Covaxin 77.8 percent effective against COVID: Lancet

Bharat Biotech has recently announced that the safety and efficacy analysis data from Phase III clinical trials of COVAXIN is peer reviewed and published in The Lancet.

The Lancet peer-review confirms the efficacy analysis which demonstrates COVAXIN to be effective against COVID-19. COVAXIN is the only COVID-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the delta variant at 65.2%.

For more details, check out the full story on the link below:

Phase 3 Data Shows Covaxin 77.8 Percent Effective Against Covid-19, Says Lancet